๐Ÿ“Œ Important: How the Irish data in this dashboard was produced
Ireland has never conducted a national dementia prevalence survey. This means there are no exact, measured Irish figures for how many people have dementia. Every number you see for Ireland in this dashboard โ€” case counts, age breakdowns, gender splits, county estimates โ€” is a scientific estimate, not a counted fact.

These estimates are produced using the following method:
Step 1: Take prevalence rates measured across Europe by the Alzheimer Europe / Eurodem consortium โ€” large, well-validated studies across multiple European countries.
Step 2: Apply those European rates to Ireland's CSO Census 2022 population data โ€” broken down by age group and county.
Step 3: The result is a credible estimate โ€” but it assumes Ireland's dementia rates mirror European averages, which may not be exactly true.
The peer-reviewed Irish study (Cahill et al. 2019, Irish Journal of Psychological Medicine) found the total could range from 39,272 to 65,266 depending on which European rates are applied, and explicitly states: "Without a national prevalence study it is not possible to be precise about the estimates of the number of people with dementia in Ireland."

What IS measured directly in Ireland: The annual new cases figure (11,000 โ€” Alzheimer Society of Ireland), the economic cost study (Connolly et al. 2014, NUI Galway), and the 2050 projection (Alzheimer Europe 2020, cited by ASI). These rest on a firmer evidential base.

The case for a national Irish prevalence survey has never been stronger โ€” and this dashboard is a direct illustration of why one is needed.
Total cases (est. 2025)
~64,000
People living with dementia in Ireland
Source: Alzheimer Society of Ireland 2025
New cases per year
11,000
Estimated annual new diagnoses
Source: Alzheimer Society of Ireland
Women affected
~2 in 3
Women make up ~63% of all cases
Source: Alzheimer Europe 2025
Economic cost (2010)
โ‚ฌ1.69bn
Annual cost; 48% informal care
Source: Connolly et al. 2014, NUI Galway
โ„น๏ธ

Alzheimer's disease accounts for approximately 60โ€“70% of all dementia cases. Vascular dementia, Lewy body dementia, and frontotemporal dementia make up the remainder. Learn more at Alzheimer Europe โ†’

Historical Trend in Ireland
Estimated cases 2000โ€“2025 ยท Source: ASI / Alzheimer Europe
Gender Split by Age Band
2025 estimates ยท Source: Alzheimer Europe 2025
Age-Specific Prevalence Rates
% of each age group estimated to have dementia ยท Source: Alzheimer Europe / Eurodem
60โ€“64
0.5%
Est.
65โ€“69
1.3%
Est.
70โ€“74
3.1%
Est.
75โ€“79
6.3%
Est.
80โ€“84
12.9%
Est.
85โ€“89
24.4%
Est.
90+
37.5%
Est.
โš ๏ธ

Age-specific rates are drawn from the Alzheimer Europe / Eurodem consortium methodology. Applied to Irish census population data (CSO 2022). No Ireland-specific age-stratified study exists.

Dementia Type Breakdown
Approximate distribution โ€” Source: WHO / Alzheimer Europe
Cases today (2025)
~64,000
2025 ASI baseline estimate
Source: ASI 2025
Projected 2045
150,000+
More than double today
Source: ASI / Alzheimer Europe
Projected 2050
141,200
Alzheimer Europe official figure
Source: Alzheimer Europe 2020 report
New cases/year
11,000
Current annual incidence
Source: Alzheimer Society of Ireland
โš ๏ธ

These projections assume no major treatment breakthroughs. Alzheimer Europe (2020) projects 141,200 cases in Ireland by 2050 โ€” this is the most widely cited official figure. The ASI states cases will exceed 150,000 by 2045. Both use different base years and methodologies. See the Global Scenarios section for how treatments could change this outlook.

Ireland Dementia Prevalence: 2000โ€“2050
Shaded area = uncertainty range ยท Historical data from ASI; projections from Alzheimer Europe 2020
Growth Per Decade
% increase per 10-year period โ€” modelled from ASI / Alzheimer Europe data
What This Means for Carers
Source: Connolly et al. 2014 (NUI Galway) ยท ASI
Annual economic cost of dementia in Ireland (2010 estimate, peer-reviewed)
โ‚ฌ1.69 billion Connolly et al. 2014
Share attributable to informal (family) care
48% of total cost โ€” largest single component
Share attributable to residential care
43% of total annual cost
๐Ÿ“Œ

Note: the โ‚ฌ1.69bn figure is from 2010 data. With today's larger caseload and higher care costs, the true 2025 figure is substantially higher โ€” a 2024 update has not been published for Ireland specifically. The updated Irish estimate is approximately โ‚ฌ1.9 billion (Connolly et al. in ScienceDirect 2024).

Women โ€” share of cases
~63%
Women consistently over-represented
Source: Alzheimer Europe 2025
Men โ€” share of cases
~37%
Partly due to longer female lifespan
Source: Alzheimer Europe 2025
Peak age group (cases)
85โ€“89
Highest total case count โ€” women
Source: Eurodem age-specific rates
Risk doubles every
5 yrs
After age 65, risk doubles per 5 years
Source: Alzheimer Europe / WHO
โ„น๏ธ

The higher proportion of women largely reflects longer life expectancy, as dementia risk rises steeply with age. Women are also disproportionately represented as unpaid family carers โ€” the Lancet 2024 Commission specifically notes gender as a social determinant of dementia care burden. Lancet 2024 โ†’

Cases by Age Band โ€” Men vs Women
2025 estimates ยท Applied Alzheimer Europe/Eurodem age-specific rates to CSO 2022 census data
Female Share by Age Band
% of cases that are women โ€” increases sharply with age
Proportional Gender Split per Age Group
โš ๏ธ

Important limitation: There is no national dementia prevalence survey in Ireland. Cahill et al. (Irish Journal of Psychological Medicine, 2019) state explicitly: "Without a national prevalence study it is not possible to be precise about the estimates of the number of people with dementia in Ireland." County figures here are generated by applying the national average rate to CSO 2022 population data. They are planning estimates only โ€” not survey results.

Kilkenny population (CSO 2022)
105,474
Based on CSO Census 2022
Source: CSO Census 2022
Kilkenny est. cases 2025
~1,300
National rate applied to 2022 population
Modelled estimate โ€” not a survey figure
National rate applied
~1.2%
ASI / Alzheimer Europe blended rate
Source: ASI 64,000 รท CSO pop. 2025
Preventable (45% PAF)
~585
If all 14 Lancet risk factors addressed
Source: Lancet 2024 Commission
Top 15 Counties โ€” Estimated Cases 2025
Kilkenny highlighted in teal ยท All figures are modelled estimates using national rate ร— CSO 2022 population
All Counties โ€” Modelled Estimates
National average rate applied to CSO 2022 census population ยท These are planning figures, not clinical counts
๐Ÿ“–

Primary source: Livingston G et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572โ€“628. DOI: 10.1016/S0140-6736(24)01296-0 ยท Read full paper (open access) โ†’

Modifiable risk factors (2024)
14
Up from 12 in 2020 report
Source: Lancet Commission 2024
Potentially preventable cases
45%
If all 14 risk factors were fully addressed
Source: Lancet Commission 2024
New in 2024 report
2
Vision loss + high LDL cholesterol
Source: Lancet Commission 2024
Largest single factor
Hearing
~7% PAF โ€” largest modifiable factor
Source: Lancet Commission 2024
Population Attributable Fraction by Risk Factor
PAF = estimated % of dementia cases linked to each factor ยท Amber = new in 2024
Risk Factor Reference Table
Source: Lancet Commission 2024 โ€” all PAF values are global estimates
โš ๏ธ

This calculator is an illustrative population-level modelling tool only. It is not a validated clinical instrument and should not be used for individual patient risk assessment. PAF values and relative risks are from Lancet Commission 2024 global data โ€” they may not perfectly reflect the Irish population. Maximum modelled reduction is capped at 45% (the Lancet 2024 global PAF total).

Adjust Population-Level Risk Reduction
Set each slider to the % reduction in that risk factor you estimate is achievable

Estimated cases preventable in Ireland

0
adjust sliders to calculate

Remaining cases~64,000
% reduction0%
Max possible (Lancet 2024)45%
Source: Lancet Commission 2024 (Livingston et al.)
PAF methodology โ€” illustrative model only
๐ŸŒ

Global context: The WHO and Alzheimer's Disease International estimate approximately 55 million people worldwide live with dementia today. Alzheimer Europe (2025) reports 12.1 million in Europe, projected to reach 19.9 million by 2050. Sources: Alzheimer Europe prevalence โ†’

Europe today (2025)
12.1m
Verified: Alzheimer Europe 2025 report
Source: Alzheimer Europe 2025
Europe projected 2050
19.9m
No-intervention baseline
Source: Alzheimer Europe 2025
Ireland 2050 (central)
141,200
Official Alzheimer Europe projection
Source: Alzheimer Europe 2020
Ireland 2045 (ASI figure)
150,000+
ASI uses different base year/method
Source: Alzheimer Society of Ireland
โ›” Pessimistic Scenario
~168,000
Ireland by 2050
No major treatment breakthroughs. Prevention investment stalls. Rapid population ageing drives continued growth. This scenario assumes the upper bound of Alzheimer Europe uncertainty ranges.
Basis: Alzheimer Europe 2020 high-bound projection
๐Ÿ”„ Central Scenario
141,200
Ireland by 2050 (official figure)
The official Alzheimer Europe (2020) central projection for Ireland, cited by the Alzheimer Society of Ireland and Irish Times. Moderate prevention gains. New drugs slow progression in a subset of patients.
Source: Alzheimer Europe 2020 ยท Irish Times Feb 2020
โœ… Optimistic Scenario
~90,000โ€“100,000
Ireland by 2050 (theoretical)
Strong population-level implementation of all 14 Lancet risk factors. Disease-modifying treatments at scale by 2035. Blood biomarker screening enabling earlier intervention. Theoretical โ€” not an official projection.
Basis: Lancet 2024 45% PAF applied to central projection
Ireland: Three Scenarios to 2050
Central scenario is from Alzheimer Europe 2020. Others are modelled upper/lower bounds.
Key Variables That Determine the Outcome
Source: Lancet 2024 ยท Alzheimer Europe 2025
Prevention (under our control now โ€” Lancet 2024)
Risk factor reduction โ€” Ireland progress
Partial
Early diagnosis rates
Improving
Treatment (dependent on research โ€” not yet accessible in Ireland)
Disease-modifying drugs (EU approved)
Not yet EMA approved
Blood biomarker screening at scale
Not yet in Ireland
๐Ÿ’Š

For decades, dementia had no disease-modifying treatments โ€” only drugs that managed symptoms. That has now changed. The first medications that can genuinely slow Alzheimer's progression were approved in the US in 2023 and 2024. These drugs are not yet approved in Europe (EMA review ongoing as of early 2026). This is a historic shift, but these are not cures. Browse active trials โ†’

FDA approved (2023โ€“24)
2
First disease-modifying Alzheimer's drugs
Source: FDA.gov (verified)
EMA status (March 2026)
Pending
Not yet approved for use in Europe / Ireland
Source: EMA.europa.eu
In Phase 3 trials globally
12+
Advanced clinical testing worldwide
Source: ClinicalTrials.gov
Historical failure rate
99%
For Alzheimer's drugs historically
Source: Alzheimer's Research UK
Lecanemab (Leqembi)
โœ“ FDA Approved โ€” July 2023
Type: Anti-amyloid monoclonal antibody  |  Company: Eisai / Biogen
Targets and removes amyloid plaques from the brain. Phase 3 (CLARITY-AD, n=1,795) showed 27% slowing of cognitive decline over 18 months vs placebo. Requires fortnightly IV infusions and regular MRI monitoring for ARIA (brain swelling/bleeds). EMA review ongoing โ€” not approved in Europe or Ireland as of March 2026.
Slowing of clinical decline vs placebo (CDR-SB scale)
27% slowing ยท Source: van Dyck et al. NEJM 2023
Donanemab (Kisunla)
โœ“ FDA Approved โ€” July 2024
Type: Anti-amyloid monoclonal antibody  |  Company: Eli Lilly
Also targets amyloid plaques. Phase 3 (TRAILBLAZER-ALZ 2) showed 35% slowing of decline in early symptomatic Alzheimer's in the overall population; 60% slowing in those with lower tau levels. Given until amyloid clearance is achieved โ€” potentially for a limited course. EMA review ongoing โ€” not approved in Europe or Ireland as of March 2026.
Slowing of clinical decline vs placebo (iADRS scale)
35% slowing overall ยท 60% in low-tau group ยท Source: Sims et al. JAMA 2023
Tau-targeting drugs
Phase 2โ€“3 Trials
Targets: Tau tangles โ€” the second hallmark of Alzheimer's  |  Multiple companies
Unlike the approved drugs which target amyloid, tau drugs target the neurofibrillary tangles that correlate more closely with cognitive decline. Several anti-tau antibodies (semorinemab, gosuranemab, zagotenemab) have had Phase 2 setbacks, but newer approaches including tau PET-guided selection are in active trials. This remains a critical research frontier.
GLP-1 Receptor Agonists (e.g. Semaglutide)
Phase 3 Trials
Known as: Ozempic / Wegovy  |  Company: Novo Nordisk & others
Drugs already approved for diabetes and obesity. Observational studies found significantly lower dementia rates in users. EVOKE trial (Novo Nordisk) and REMODEL trial testing directly in Alzheimer's patients. If Phase 3 confirms benefit, these widely available drugs could become a major prevention tool within 3โ€“5 years โ€” but trial results not yet available.
๐Ÿ‡ฎ๐Ÿ‡ช

For Ireland specifically: Neither lecanemab nor donanemab are available through the HSE as of March 2026. Even after EMA approval, NCPE (National Centre for Pharmacoeconomics) reimbursement assessment will be required. Memory clinic capacity โ€” already stretched with 12โ€“18 month waiting times โ€” will be a bottleneck for eligibility assessment (requires early diagnosis + amyloid confirmation by PET or CSF).

๐Ÿค–

The Lancet 2024 Commission specifically highlights advances in fluid biomarkers for blood-based detection of Alzheimer's disease as one of the most significant recent developments. Blood biomarker testing (particularly plasma p-tau217) is becoming routine in research settings and may enter Irish memory clinics within 5 years. Lancet 2024 on biomarkers โ†’

๐Ÿฉธ
Blood Biomarkers (p-tau217)
In use in research
Plasma phosphorylated tau 217 (p-tau217) can detect Alzheimer's pathology up to 20 years before symptoms. Accuracy now comparable to PET scans in research settings. Clinical implementation in Ireland not yet available โ€” but expected within 3โ€“7 years as the Lancet 2024 Commission specifically recommends this pathway. Lancet 2024 โ†’
๐Ÿ‘๏ธ
Retinal Imaging (AI)
In clinical trials
AI analysis of retinal scans can detect amyloid and vascular changes associated with Alzheimer's up to 5 years before clinical symptoms. The retina is an extension of the brain โ€” changes mirror those in the cerebral cortex. Trials underway in the UK and US. Not yet clinical standard.
๐ŸŽ™๏ธ
Speech & Language Analysis
In clinical trials
AI systems analysing speech patterns (pause duration, word-finding, semantic content) can identify subtle changes years before diagnosis. Studies show 80โ€“90% accuracy in controlled settings. DementiaBank and ADReSS datasets are widely used in research. The Framingham Heart Study used speech data to predict dementia over 10 years.
๐Ÿง 
MRI & PET AI Analysis
Research & emerging clinical
Deep learning algorithms can detect subtle structural brain changes in MRI scans that are invisible to the human eye. FDA has cleared several AI-assisted MRI analysis tools. PET amyloid imaging is currently required to confirm eligibility for lecanemab/donanemab โ€” creating a capacity bottleneck that MRI AI tools may eventually help address.
โŒš
Wearable Cognitive Monitoring
Research phase
Smartwatches and rings tracking sleep patterns, gait, reaction time, and heart rate variability can detect subtle signs of cognitive decline months before clinical presentation. Apple, Samsung, and Oura are partnering with researchers. No clinical-grade product yet validated for diagnostic use โ€” but likely within 5 years.
๐Ÿ’ป
Digital Cognitive Testing
Available now (research)
Tablet-based and smartphone cognitive tests (e.g. Cogstate, Cambridge Cognition) are being validated as screening tools for primary care. More sensitive than traditional MMSE at detecting early-stage Mild Cognitive Impairment (MCI). Some are now used in clinical trials for patient selection. Cogstate โ†’
๐Ÿ”ญ

Beyond the current drug pipeline, a broader revolution in neuroscience is underway. These approaches are earlier-stage โ€” some could prove transformative, others will fail. We present them honestly: promising but uncertain. Confidence levels are based on stage of evidence, not optimism. This is what scientific progress actually looks like.

Emerging Approaches โ€” Timeline to Patients
Ordered by expected time to widespread access
2026โ€“2030 ยท High confidence
Combination amyloid + tau therapies
Attacking both hallmarks of Alzheimer's simultaneously. If Phase 3 tau trials succeed, combination therapy could slow decline by 50โ€“60%. Multiple trials active. This is the most likely near-term advance. ClinicalTrials.gov โ†’
High confidencePhase 2โ€“3
2028โ€“2033 ยท Moderate confidence
Population blood biomarker screening
National programmes offering plasma p-tau217 tests to people aged 50+ to detect Alzheimer's pathology before symptoms. Pilot programmes running in Sweden and the US. The Lancet 2024 Commission specifically recommends this pathway. Ireland would need major investment in memory clinic capacity to act on results.
Moderate confidencePolicy decision needed
2030โ€“2038 ยท Speculative
Neuroinflammation targeting
Microglia โ€” the brain's immune cells โ€” play a key role in dementia progression. Drugs targeting neuroinflammation are in early trials. Could be especially relevant for vascular and Lewy body dementia, which currently have no disease-modifying treatments at all.
SpeculativePhase 1โ€“2
2033โ€“2045 ยท Long horizon
Gene therapy for APOE4 carriers
People carrying two copies of APOE4 have up to 12ร— higher Alzheimer's risk. Gene silencing or editing could substantially reduce risk. CRISPR human trials are beginning. Enormous potential โ€” but a 10โ€“20 year horizon to widespread patient access. PubMed APOE4 gene therapy โ†’
Long horizonPhase 1
2040โ€“2055 ยท Very speculative
Neuroregeneration & stem cells
Replacing lost neurons using stem cell therapies. Even if new cells can be introduced, re-wiring the brain's complex connections remains profoundly difficult. This remains a long-term scientific aspiration. Worth watching โ€” but not imminent.
Very speculativePreclinical stage
What Would a "Cure" Actually Look Like?
๐ŸŽฏ

Most scientists believe a complete cure โ€” restoring lost memories โ€” is unlikely in the next 25 years. The more realistic and impactful goal is delay and prevention: pushing back onset by 5โ€“10 years for most people would halve the number of people living with severe dementia at any one time.

Impact of delaying onset at population level (modelling, not a trial result):
Delay by 2 years
~20% fewer severe cases
Delay by 5 years
~40% fewer severe cases
Delay by 10 years
~57% fewer severe cases
The Gap: Non-Alzheimer's Dementias
Often overlooked in the drug pipeline
โš ๏ธ

Almost all drug pipeline activity focuses on Alzheimer's. Lewy body, vascular, and frontotemporal dementia โ€” affecting 30โ€“40% of all patients โ€” have no disease-modifying treatments in advanced trials. This is a major gap in global research investment.

Active research directions: alpha-synuclein targeting (Lewy body), cardiovascular risk control (vascular), TDP-43 protein modulation (frontotemporal). None near approval.
Evidence-Based Prediction: Ireland in 2040
Based on current evidence and pipeline trajectory, by 2040 it is reasonable to expect: blood biomarker tests available in Irish memory clinics; subcutaneous anti-amyloid drugs approved in Europe; AI-assisted early detection used in specialist settings; 5โ€“10% reduction in severe dementia rates in countries with strong prevention programmes.

It is possible but uncertain: GLP-1 drugs approved for Alzheimer's prevention; population blood screening programmes; gene therapy trials for APOE4 carriers.

It remains unlikely by 2040: a cure; reversal of established cognitive decline; effective treatment for later-stage dementia.
โœ…

While we wait for the next generation of treatments, there is a substantial amount that can be done today to improve outcomes, quality of life, and delay progression โ€” for both people living with dementia and those who care for them. The Lancet 2024 Commission provides extensive evidence-based guidance on interventions. Lancet 2024 full text โ†’

๐Ÿฉบ
For Clinicians & GPs
CLINICIAN
  • Refer early to memory assessment services โ€” earlier diagnosis unlocks post-diagnostic support, legal planning, and access to clinical trials; the new anti-amyloid drugs require early-stage disease
  • Screen and aggressively treat vascular risk โ€” hypertension, diabetes, high LDL cholesterol, and atrial fibrillation are all modifiable now, and all reduce dementia risk (Lancet 2024)
  • Prescribe hearing aids โ€” hearing loss is the single largest modifiable risk factor; correction may meaningfully slow cognitive decline
  • Review polypharmacy carefully โ€” anticholinergic medications significantly increase dementia risk; structured annual review in patients over 65 is recommended
  • Provide post-diagnostic planning โ€” advance care directives, driving assessment, capacity assessment, medication review
  • Refer carers โ€” carer stress, depression and burnout are themselves health risks; ASI provides free support for carers
๐Ÿ‘จโ€๐Ÿ‘ฉโ€๐Ÿ‘ง
For Family Carers
FAMILY CARER
  • Use HSE home support hours โ€” contact your GP or public health nurse; day centres and overnight respite are available through HSE
  • Use structured daily routines โ€” predictability and familiarity significantly reduce agitation, anxiety, and challenging behaviour
  • Dementia-proof the home โ€” door alarms, stove guards, grab rails, good lighting; OT assessment via GP referral
  • Engage with the Alzheimer Society of Ireland โ€” free home visits, carer support groups, helpline 1800 341 341 (7 days a week, free of charge)
  • Plan legal and financial matters early โ€” Enduring Power of Attorney must be established while the person still has legal capacity; do not delay. Citizens Information guide โ†’
  • Use GPS tracking โ€” discreet wearable trackers (AngelSense, Mindme) prevent dangerous wandering incidents; among highest-impact low-cost interventions
๐Ÿง˜
For People Living With Dementia
PERSON
  • Stay physically active โ€” regular walking is the most evidence-backed activity to slow cognitive decline; aim for 30 minutes most days
  • Stay socially connected โ€” social isolation is the 6th largest modifiable risk factor (Lancet 2024); Alzheimer cafรฉs and community groups make a real difference
  • Engage in Cognitive Stimulation Therapy (CST) โ€” structured group programmes with randomised trial evidence for meaningful benefit CST Programme โ†’
  • Manage vascular risk factors โ€” blood pressure medication, stopping smoking, controlling diabetes all protect the brain directly
  • Pursue meaningful activity โ€” music, arts, gardening, and familiar hobbies preserve identity and wellbeing throughout the condition
  • Document your wishes now โ€” while you have capacity, record care preferences and financial wishes for future reference
๐Ÿ›๏ธ
For the Health System
SYSTEM / POLICY
  • Expand memory assessment services urgently โ€” waiting times of 12โ€“18 months are common in Ireland; anti-amyloid drug eligibility requires early diagnosis, making this bottleneck critical
  • Train all healthcare staff โ€” basic dementia awareness training should be mandatory; specialist dementia nurses should be present in every CHO area
  • Implement the National Dementia Registry โ€” the Minister for Health announced commencement of the registry in May 2025; full implementation is overdue
  • Fund community supports โ€” homecare hours, day centres, and carer respite are more cost-effective than residential care (Connolly 2014)
  • Prepare NCPE reimbursement pathways now โ€” EMA approval of lecanemab/donanemab is expected; HSE and NCPE need decision frameworks ready before approval
  • Invest in prevention infrastructure โ€” population-level hearing screening and cardiovascular programmes deliver long-term returns
Care Technology Available Right Now in Ireland
๐Ÿ“
GPS Tracking Devices
Available Now
Discreet wearable trackers for people who may wander. AngelSense, Pixie, Mindme available in Ireland. Massively reduces carer anxiety and can prevent life-threatening incidents โ€” one of the highest-impact low-cost interventions.
๐Ÿšจ
Fall Detection & Alerts
Available Now
Personal alarms with automatic fall detection (Lifeline, Telecare) and smart home sensors. HSE Telecare programmes available in many areas โ€” ask your GP or public health nurse for a referral. HSE Telecare โ†’
๐Ÿ’Š
Automated Medication Dispensers
Available Now
Devices (Pivotell, MedMinder) dispense the correct dose at the correct time with audible reminders and carer alerts if missed. Reduces medication errors โ€” a common and preventable cause of hospitalisation in dementia.
๐ŸŽต
Music & Reminiscence Therapy
Available Now
Music from a person's youth can dramatically reduce agitation and improve mood. Playlist for Life provides evidence-based resources for carers and staff. Strong evidence base, zero side effects, accessible to all. Playlist for Life โ†’
๐Ÿ–ฅ๏ธ
Simplified Video Calling
Available Now
Amazon Echo Show and GrandPad simplify video calling. Regular face-to-face contact with family reduces social isolation โ€” the 6th largest modifiable risk factor โ€” and is free or low-cost to facilitate.
๐ŸŒ™
Night Safety Solutions
Available Now
Door sensors with audible alerts, bed exit monitors, and motion-activated soft lighting are affordable and available from HSE occupational therapy services via GP referral. Night-time wandering is one of the most distressing carer challenges.
๐Ÿ‡ฎ๐Ÿ‡ช

Key contact for Kilkenny & South East: HSE Community Healthcare โ€” Carlow Kilkenny Dementia Advisor service provides free, personalised guidance for people with dementia and their carers. Contact through your GP or directly via HSE South East. National helpline: 1800 341 341 (Alzheimer Society of Ireland โ€” free, 7 days a week, 9amโ€“5pm).

๐Ÿ‡ฎ๐Ÿ‡ช Ireland โ€” Key Contacts
Alzheimer Society of Ireland
National helpline โ€” free, 7 days, 9amโ€“5pm
1800 341 341
alzheimer.ie โ†’
HSE Dementia Pathways
Referral pathways & resource finder
HSE.ie
hse.ie/dementia-pathways โ†’
Dementia Ireland
Community & peer support
dementia.ie
dementia.ie โ†’
๐Ÿฅ
National Organisation
Alzheimer Society of Ireland
Ireland's leading dementia charity. Helpline, home visits, day services, advocacy, and carer support. Free, 7 days a week.
๐Ÿง 
Clinical Pathway
HSE Dementia Pathways
National referral pathways, memory assessment services, and clinical resources for healthcare professionals in Ireland.
๐Ÿ‘ช
Legal & Social
Citizens Information โ€” Dementia
Full guide to entitlements, Enduring Power of Attorney, home care supports, and financial assistance in Ireland.
๐Ÿ“–
Evidence
Lancet Commission 2024
Livingston G et al. Full text of the 2024 Lancet Commission on Dementia Prevention, Intervention and Care. Open access. DOI: 10.1016/S0140-6736(24)01296-0
๐Ÿ’Š
Drug Pipeline
ClinicalTrials.gov
Live database of all active dementia and Alzheimer's clinical trials worldwide. Search by country, condition, and phase.
๐ŸŒ
Statistics
Alzheimer Europe Prevalence Data
Official European prevalence statistics including country-by-country data. Primary source for Ireland's national estimates.
๐Ÿก
Kilkenny Local
HSE South East โ€” Telecare & Dementia
Local dementia advisor, telecare referrals, and community supports for the Kilkenny / Carlow / South East area via HSE Community Healthcare.
๐ŸŽต
Care Technology
Playlist for Life
Evidence-based music therapy for dementia. Free resources for carers and healthcare staff โ€” one of the most accessible, evidence-supported interventions available.
๐Ÿ“‹
Clinical Guideline
NICE Guideline NG97 โ€” Dementia
UK National Institute for Health and Care Excellence. Assessment, diagnosis, interventions and support for people with dementia and their carers.
โš–๏ธ

This dashboard is for informational and awareness purposes only. All population figures are estimates unless otherwise stated. Clinical decisions should always be based on individual assessment, current national guidelines (HSE, NICE), and professional judgement. Data as of March 2026.

๐Ÿ“–

Each term links to a reliable external source โ€” primarily Alzheimer Europe, WHO, the Lancet, or NHS/HSE โ€” so readers can explore further. Terms are listed alphabetically.

Alzheimer's Disease
The most common form of dementia, accounting for 60โ€“70% of all cases. Caused by abnormal accumulation of amyloid plaques and tau tangles in the brain, which disrupt communication between neurons and cause cell death. It is progressive and currently has no cure, though disease-modifying treatments were approved in the US in 2023โ€“2024.
Learn more at Alzheimer Europe โ†’
Amyloid Plaques
Abnormal deposits of a protein fragment called beta-amyloid that accumulate between neurons in the brain. Considered one of the two hallmarks of Alzheimer's disease (alongside tau tangles). The approved anti-amyloid drugs (lecanemab, donanemab) work by clearing these plaques โ€” though clearing amyloid does not fully reverse the disease.
Alzheimer Europe: Causes โ†’
APOE4 Gene
A variant of the APOE gene that is the strongest known genetic risk factor for late-onset Alzheimer's disease. People who inherit two copies (one from each parent) have up to 12 times the risk of developing Alzheimer's. About 25% of the population carries at least one copy. APOE4 is not a certainty โ€” it is a risk factor, not a diagnosis.
ASI: Genetics and dementia โ†’
Biomarker
A measurable biological indicator of a disease process. In dementia, biomarkers include blood tests (e.g. plasma p-tau217), PET brain scans showing amyloid or tau deposits, and cerebrospinal fluid (CSF) tests. Blood biomarkers are the most exciting recent development because they are cheaper, less invasive, and scalable as a screening tool.
Lancet 2024 on biomarkers โ†’
Cognitive Reserve
The brain's resilience to damage โ€” built up through education, mentally stimulating work, social engagement, and lifelong learning. People with higher cognitive reserve can sustain more brain damage before showing symptoms. This is why less education is the single largest modifiable risk factor in the Lancet model โ€” it reduces cognitive reserve.
Alzheimer Europe: Cognitive Reserve โ†’
Cognitive Stimulation Therapy (CST)
A structured group programme for people with mild-to-moderate dementia, typically run by healthcare professionals. Involves themed activities designed to engage thinking and memory. Multiple randomised controlled trials show modest but meaningful improvements in cognition and quality of life. Evidence-based and recommended by NICE guidelines.
CST Programme website โ†’
Dementia
An umbrella term for a group of conditions that cause progressive decline in memory, thinking, behaviour, and ability to carry out daily activities. Dementia is not a normal part of ageing. Alzheimer's disease is the most common type; others include vascular dementia, Lewy body dementia, and frontotemporal dementia. It affects over 64,000 people in Ireland.
Alzheimer Europe: What is dementia? โ†’
Disease-Modifying Treatment
A treatment that directly affects the disease process itself โ€” not just managing symptoms. Until 2023, no disease-modifying treatments existed for Alzheimer's. Lecanemab and donanemab are the first โ€” they slow progression by removing amyloid from the brain. They are not cures, but they represent the first time a treatment has changed the underlying biology of the disease.
ASI: New Alzheimer's drugs โ†’
Enduring Power of Attorney (EPA)
A legal document that allows a person to appoint someone they trust to make decisions on their behalf if they lose mental capacity. In Ireland, it must be set up while the person still has capacity โ€” it cannot be created after a diagnosis of moderate or severe dementia. Citizens Information provides detailed guidance for Ireland.
Citizens Information: EPA in Ireland โ†’
Frontotemporal Dementia (FTD)
A type of dementia affecting the frontal and temporal lobes of the brain โ€” areas governing personality, behaviour, and language. Unlike Alzheimer's, memory is often relatively preserved early on; instead, personality change, disinhibition, and language difficulties are prominent. Often diagnosed at a younger age (50sโ€“60s). No disease-modifying treatment exists.
Alzheimer Europe: FTD โ†’
Lancet Commission on Dementia
An ongoing international scientific commission established by The Lancet medical journal, led by Professor Gill Livingston (UCL). Published landmark reports in 2017, 2020, and 2024, each identifying modifiable risk factors and evidence-based interventions. The 2024 report identified 14 risk factors accounting for 45% of cases. Fully open access.
Read the 2024 Commission โ†’
Lewy Body Dementia (LBD)
The second most common type of progressive dementia after Alzheimer's. Caused by abnormal deposits of a protein called alpha-synuclein (Lewy bodies) in brain cells. Key symptoms include visual hallucinations, fluctuating cognition, sleep disturbances, and Parkinson's-like movement problems. Diagnosis is often delayed. No disease-modifying treatment exists.
Alzheimer Europe: Lewy Body โ†’
Mild Cognitive Impairment (MCI)
A stage between normal cognitive ageing and dementia. People with MCI have noticeable memory or cognitive problems but can still carry out daily activities independently. Approximately 10โ€“15% of people with MCI progress to dementia per year. MCI due to Alzheimer's disease is now the target for the new disease-modifying treatments (lecanemab, donanemab).
Alzheimer Europe: MCI and stages โ†’
PAF โ€” Population Attributable Fraction
The proportion of disease cases in a population that is theoretically preventable if a specific risk factor were completely eliminated. Used in the Lancet Commission to estimate how many dementia cases could be prevented. For example, a PAF of 7% for hearing loss means that 7% of all dementia cases are linked to hearing loss โ€” and could theoretically be prevented with hearing correction. PAFs do not simply add up; they are calculated together accounting for overlap.
Lancet 2024: PAF methodology โ†’
p-tau217 (Plasma Phospho-Tau 217)
A blood biomarker that detects abnormal tau protein in the blood โ€” a sign of Alzheimer's pathology. One of the most promising early detection tools: studies show 90%+ accuracy in identifying Alzheimer's disease up to 20 years before symptoms. Currently used in research and specialist clinical settings. The Lancet 2024 Commission recommends clinical implementation as part of future diagnostic pathways.
Lancet 2024 on p-tau217 โ†’
Tau Tangles
Abnormal twisted fibres of tau protein that form inside neurons in Alzheimer's disease and some other dementias. Together with amyloid plaques, they are the two defining hallmarks of Alzheimer's. Tau pathology correlates more closely with cognitive decline than amyloid. Anti-tau drugs are in clinical trials but none have yet been approved. The Braak staging system tracks the spread of tau through the brain.
Alzheimer Europe: Tau tangles โ†’
Vascular Dementia
The second most common type of dementia, caused by reduced blood supply to the brain โ€” often following strokes or small vessel disease. Symptoms vary depending on which areas of the brain are affected but commonly include problems with speed of thinking, concentration, and planning. The most directly preventable type of dementia: controlling blood pressure, diabetes, cholesterol, and stopping smoking all reduce risk substantially.
Alzheimer Europe: Vascular dementia โ†’
๐Ÿ”ฌ Critical Methodology Statement โ€” For Specialists
Ireland has no national dementia prevalence survey. This is the single most important limitation of all Irish dementia data, and it must be understood before interpreting any figure in this dashboard.

Where do the Irish numbers come from?
All case estimates, age-specific rates, gender breakdowns, and county figures in this dashboard originate from European prevalence studies โ€” primarily the Alzheimer Europe / Eurodem consortium, which pooled data from large population studies across multiple European countries (Netherlands, France, UK, Spain, Italy, Germany). These European rates are then mathematically applied to Ireland's CSO Census 2022 population data to produce Irish estimates.

This method has been used by: the Alzheimer Society of Ireland, the HSE National Dementia Office, and Alzheimer Europe itself when reporting Irish figures. It is the best available method โ€” but it is not the same as directly measuring dementia in Ireland.

Known limitations:
  • Ireland's rates may differ from European averages due to population structure, lifestyle factors, and healthcare access
  • The peer-reviewed range for total Irish cases is 39,272โ€“65,266 depending on which European dataset is applied (Cahill et al. 2019)
  • No county-level Irish survey has ever been conducted
  • The last comprehensive Irish-focused prevalence analysis was published in 2019
What is directly measured in Ireland: The annual incidence figure (11,000 new cases/year โ€” ASI), the economic cost study (Connolly et al. 2014 โ€” peer-reviewed Irish study using Irish cost data), and specific clinical trial data where Irish sites participated.

Cahill et al. 2019 โ€” Irish Journal of Psychological Medicine (PubMed) โ†’
Data Classification
Every major figure in this dashboard is categorised by evidence quality
Data PointValue UsedTypePrimary Source
Total Irish cases 2025~64,000ESTIMATEAlzheimer Society of Ireland 2025 โ†’
New cases per year11,000VERIFIEDAlzheimer Society of Ireland โ†’
Ireland 2050 projection141,200VERIFIEDAlzheimer Europe 2020 ยท Irish Times Feb 2020 โ†’
Ireland 2045 projection150,000+VERIFIEDAlzheimer Society of Ireland (different base year) โ†’
Annual economic costโ‚ฌ1.69bn (2010)VERIFIEDConnolly et al. 2014, NUI Galway (PubMed) โ†’
Informal care share48%VERIFIEDConnolly et al. 2014 (PubMed) โ†’
14 modifiable risk factors45% PAFVERIFIEDLancet Commission 2024 โ€” Livingston et al. DOI: 10.1016/S0140-6736(24)01296-0 โ†’
Europe total cases 202512.1 millionVERIFIEDAlzheimer Europe 2025 โ†’
Europe total cases 205019.9 millionVERIFIEDAlzheimer Europe 2025 โ†’
Lecanemab FDA approvalJuly 2023VERIFIEDFDA.gov โ†’
Lecanemab efficacy27% slowingVERIFIEDvan Dyck et al. NEJM 2023 โ†’
Donanemab FDA approvalJuly 2024VERIFIEDFDA.gov โ†’
Donanemab efficacy35% slowingVERIFIEDSims et al. JAMA 2023 โ†’
County-level case estimatesAll countiesMODELLEDNational average rate applied to CSO Census 2022 population. No county-specific survey exists. Cahill et al. 2019 (limitation noted) โ†’
Age-specific prevalence rates0.5%โ€“37.5%MODELLEDAlzheimer Europe / Eurodem consortium age-band rates applied to CSO 2022 data. Alzheimer Europe โ†’
Historical trend 2000โ€“202026kโ†’61kMODELLEDAlzheimer Europe successive annual estimates, aligned with ASI baseline figures.
Prevention calculator resultsVariableMODEL ONLYIllustrative tool using Lancet 2024 PAF values. Not a validated clinical instrument. Lancet 2024 โ†’
Key Primary Sources โ€” Full References
ReferenceLink
Livingston G et al. (2024). Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 404(10452):572โ€“628.Open access โ†’
Connolly S, Gillespie P, O'Shea E, Cahill S, Pierce M. (2014). Estimating the economic and social costs of dementia in Ireland. Dementia. 13(1):5โ€“22.PubMed โ†’
Cahill S, Pierce M, Werner P, Darley A, Bobersky A. (2019). Estimates of the prevalence, incidence and severity of dementia in Ireland. Irish Journal of Psychological Medicine. 36(2):129โ€“137.PubMed โ†’
van Dyck CH et al. (2023). Lecanemab in Early Alzheimer's Disease. New England Journal of Medicine. 388:9โ€“21.NEJM โ†’
Sims JR et al. (2023). Donanemab in Early Symptomatic Alzheimer's Disease. JAMA. 330(6):512โ€“527.JAMA โ†’
Alzheimer Europe (2025). Prevalence of dementia in Europe โ€” 2025 update. Using UN World Population Prospects 2024 data.Alzheimer Europe โ†’
Alzheimer Europe (2020). Ireland projection to 2050: 141,200 cases. Reported in Irish Times, February 2020.Irish Times โ†’
HSE National Dementia Office. Dementia Pathways โ€” clinical guidelines and referral pathways for Ireland.HSE โ†’
Alzheimer Society of Ireland. Facts and Figures. Core statistics for dementia in Ireland.alzheimer.ie โ†’
NICE Guideline NG97. Dementia: assessment, management and support for people living with dementia and their carers. Updated 2023.NICE โ†’
โค๏ธ

40% of dementia carers develop clinical depression. Burnout is a medical condition โ€” not weakness. Taking care of yourself is taking care of the person with dementia. These tools are built for you.

Daily Care Checklist
Tick each task as completed โ€” resets each day
0 of 15 completed
Communication Strategies
Enter their reality
Never argue or correct. If they believe it is 1972, step gently into that world. The goal is emotional safety and calm โ€” not factual accuracy.
One step at a time
Break all instructions into single actions. "Let's put on your left shoe." Short sentences, slow speech, constant eye contact. Repeat patiently.
Respond to the emotion
When they say "I want to go home" (and they are home), respond to the feeling: "You seem unsettled โ€” let's sit together for a moment."
Music bypasses language
Familiar music from their youth can reach someone who no longer responds to words. It lives in procedural memory โ€” the last to go.
Your calm is contagious
People with dementia are acutely sensitive to emotional tone. Take three slow breaths before any difficult interaction. Your calm is the most powerful therapeutic tool you have.
Home Safety Checklist
๐Ÿšฟ
Bathroom
  • Install grab bars by toilet and shower
  • Non-slip mats inside and outside bath
  • Set water heater below 48ยฐC
  • Remove all door locking mechanisms
  • Night lights on route to bathroom
  • ๐Ÿณ
    Kitchen
  • Automatic stove shut-off devices
  • Lock knives, chemicals, medications
  • Electric kettle with auto-shutoff
  • Label cabinets with pictures
  • Disable garbage disposal
  • ๐Ÿšถ
    Wandering Prevention
  • Door alarms and motion sensors
  • STOP signs on exterior doors
  • GPS tracking smartwatch
  • MedicAlert SafeReturn registration
  • ID bracelet at all times
  • ๐Ÿ’Š
    Medications
  • Automatic pill dispenser with alarm
  • All medications locked away
  • Master medication list for emergencies
  • Use blister packs or dosette boxes
  • Regular medication review with GP
  • Emergency Protocols
    ๐Ÿšจ

    If they go missing: Search 15 minutes maximum then call 999 immediately. Do NOT wait 24 hours. Contact Alzheimer Society Ireland: 1800 341 341. Share recent photo, GPS tracker ID, clothing description.

    โš ๏ธ

    If they become aggressive: Stay calm. Identify triggers โ€” pain, UTI, fear. Give space, never corner. Redirect gently. Document for medical team โ€” sudden aggression almost always has a physical cause.

    ๐Ÿฅ

    If they have a fall: Do not immediately lift them. Check for pain or inability to move limbs. Keep them warm and calm. If any head contact โ€” call 999.

    ๐Ÿ“ž

    Key Ireland Numbers:
    Alzheimer Society Ireland Helpline: 1800 341 341
    HSE Carers Support: 1800 24 1850
    Emergency: 999 / 112
    Samaritans (carers in crisis): 116 123

    โ„น๏ธ

    Not everyone progresses through all stages in a straight line. Some stages overlap. Some people plateau. The pace varies enormously โ€” from 3 to 20 years total duration. These stages describe the general pattern, not a fixed timeline.

    โš ๏ธ

    Important: This is an educational tool only. A score here cannot diagnose or exclude dementia. Many factors affect performance โ€” anxiety, fatigue, education level, language. Only a qualified clinician can make a diagnosis using validated tools in a proper clinical setting.

    Brain Regions Affected
    Click any region for detail
    tap a region
    Hippocampus Prefrontal Temporal Parietal Occipital Basal Forebrain
    Select a brain region
    Click any coloured area on the brain diagram

    The brain illustration shows the six main regions affected by Alzheimer's disease โ€” each coloured differently. The pulsing red circles mark the hippocampus โ€” the first region damaged, responsible for forming new memories. Click any region to learn what it does and how Alzheimer's affects it.

    โš ๏ธ

    This symptom checker is for educational purposes only. If you are concerned about someone's memory or behaviour, please contact your GP as the first step. Early assessment is always worthwhile.

    Risk reduction โ€” exercise
    30โ€“45%
    With 150 min/week aerobic exercise
    MIND diet adherents
    53%
    Lower Alzheimer's risk in strict followers
    Sleep deprivation
    1 night
    Enough to raise amyloid in CSF measurably
    Social isolation risk
    2.4ร—
    Higher dementia risk if socially isolated
    The MIND Diet โ€” 10 Brain-Healthy Foods
    Mediterranean-DASH Intervention for Neurodegenerative Delay
    ๐Ÿฅฌ
    Leafy Green Vegetables
    6+ servings per week. Spinach, kale, collards. Highest association with slower cognitive decline.
    ๐Ÿซ
    Berries
    2+ servings per week. Blueberries and strawberries most studied. Rich in flavonoids that protect neurons.
    ๐Ÿฅœ
    Nuts
    5+ servings per week. Walnuts especially โ€” high in omega-3. Reduce neuroinflammation.
    ๐Ÿซ’
    Olive Oil
    Primary cooking oil. Oleocanthal has anti-inflammatory properties similar to ibuprofen.
    ๐ŸŸ
    Fish
    1+ serving per week. Oily fish (salmon, mackerel, sardines) highest in DHA omega-3.
    ๐Ÿซ˜
    Beans & Legumes
    4+ meals per week. Chickpeas, lentils, kidney beans. Fibre feeds gut-brain axis.
    ๐Ÿท
    Red Wine (moderate)
    1 glass per day maximum. Resveratrol may protect neurons โ€” but excess alcohol is a dementia risk.
    ๐Ÿ—
    Poultry
    2+ servings per week. Lean protein. Replace red meat which increases inflammation.
    Lifestyle Pillars for Brain Health
    Physical Exercise โ€” Most Powerful
    150 minutes per week of moderate aerobic activity. Walking, swimming, cycling. Increases BDNF (brain-derived neurotrophic factor) โ€” literally grows new brain cells. Even starting at 70 years old has measurable benefit.
    30โ€“45% risk reductionAny age helps
    Sleep โ€” The Brain's Cleaning Cycle
    7โ€“9 hours of quality sleep per night. During deep sleep the glymphatic system flushes amyloid-beta from brain tissue. Chronic sleep deprivation is one of the fastest ways to accelerate amyloid accumulation. Treat sleep apnea โ€” it dramatically raises tau levels.
    7โ€“9 hours targetTreat sleep apnea
    Cognitive Stimulation
    Learning new skills, reading, puzzles, musical instruments, a second language. Builds cognitive reserve โ€” the brain's ability to compensate for damage. People with higher education and cognitive engagement show symptoms years later despite identical pathology.
    Lifelong learningAny new skill counts
    Social Connection
    Social isolation increases dementia risk 2.4ร—. Regular meaningful social interaction protects the brain through multiple mechanisms โ€” reducing stress hormones, stimulating cognitive engagement, and providing emotional regulation. Quality matters more than quantity.
    2.4ร— risk if isolated
    Stress Management
    Chronic stress elevates cortisol which directly damages the hippocampus. Mindfulness, meditation, yoga, and nature walks all reduce cortisol. Even 10 minutes of daily mindfulness has measurable effects on brain inflammation markers.
    Cortisol damages hippocampus
    Avoid Smoking & Excess Alcohol
    Smoking doubles stroke risk and accelerates cerebrovascular damage. Excess alcohol (more than 14 units per week) is a direct neurotoxin and a significant dementia risk factor โ€” it is also the cause of Korsakoff syndrome. Stopping smoking at any age reduces risk significantly.
    Stop smoking โ€” any ageMax 14 units/week
    ASI Helpline
    1800 341 341
    Free ยท Mondayโ€“Friday 10amโ€“5pm
    HSE Carers Line
    1800 24 1850
    Free ยท Support for family carers
    Citizens Information
    0818 07 4000
    Benefits, entitlements, legal rights
    Emergency
    999 / 112
    For immediate safety emergencies
    Financial Entitlements in Ireland
    Benefits and allowances available โ€” source: Citizens Information
    BenefitWho It Is ForAmount / Details
    Carer's AllowanceFull-time family carersUp to โ‚ฌ248/week ยท Means tested ยท Apply to DSP
    Carer's BenefitEmployees leaving work to careโ‚ฌ249/week ยท Up to 2 years ยท PRSI based
    Carer's Support GrantAll carersโ‚ฌ1,850 per year ยท Paid annually in June
    Disability AllowancePerson with dementia under 66Up to โ‚ฌ232/week ยท Means tested
    State PensionPerson with dementia over 66Up to โ‚ฌ277/week ยท Contributory or Non-contributory
    Medical CardLow income / over 70sFree GP, hospital, prescriptions ยท Apply to HSE
    Fair Deal SchemeNursing home care80% of income + 7.5% assets per year ยท HSE scheme
    Home Care PackageLiving at home with supportFree HSE home care hours ยท Apply via GP/public health nurse
    Respite Care GrantFamily carersโ‚ฌ1,850/year to fund a break from caring
    ๐Ÿ’ก

    Many families miss out on thousands of euros in entitlements because they do not know they exist. Contact Citizens Information (0818 07 4000) or the Alzheimer Society helpline to check what you are entitled to.

    Legal Planning โ€” Do It Early
    Legal capacity diminishes as dementia progresses โ€” planning while capacity exists is essential
    Enduring Power of Attorney (EPA)
    Do This First
    Appoints someone to make decisions about property, finances, and personal welfare if the person loses capacity. Must be set up while the person still has legal capacity. A solicitor is required. Cost approximately โ‚ฌ500โ€“โ‚ฌ1,500.
    Will
    Essential
    Must be made or updated while the person has testamentary capacity. A solicitor should assess capacity at the time of signing. Without a will, assets are distributed by law regardless of the person's wishes.
    Decision Support Agreement
    New in Ireland 2023
    Under the Assisted Decision-Making (Capacity) Act 2015 โ€” now in force. Allows a person to formally appoint a decision-making assistant while they still have capacity. Registered with the Decision Support Service.
    Advance Healthcare Directive
    Strongly Recommended
    Documents the person's wishes about medical treatment if they lose capacity to decide. Includes CPR, hospital admission, feeding tubes, and end-of-life preferences. Now legally recognised in Ireland under the 2015 Act.
    โ„น๏ธ

    Mixed dementia โ€” most commonly Alzheimer's combined with vascular pathology โ€” is found at autopsy in up to 50% of dementia cases. Many patients receive a single diagnosis that understates the true complexity. Use the sidebar to explore each type in full clinical depth.

    TypePrevalenceTypical OnsetFirst SymptomReversible?Primary Prevention
    ๐Ÿง  Alzheimer's Disease60โ€“80%Usually 65+Memory lossNoExercise ยท BP control ยท Hearing aids
    ๐Ÿซ€ Vascular Dementia10โ€“15%60โ€“75Sudden cognitive drop / strokePartiallyBP control ยท Treat AF ยท Statins
    ๐Ÿ‘๏ธ Lewy Body Dementia5โ€“10%70โ€“85Visual hallucinations ยท RBDNoโš ๏ธ Avoid antipsychotics
    ๐ŸŽญ Frontotemporal (FTD)5%45โ€“65 (young)Personality / behaviour changeNoGenetic counselling
    ๐Ÿ’ง Normal Pressure Hydrocephalus~5%60โ€“80Gait disturbance (triad)YES โ€” if treatedLP tap test ยท VP shunt surgery
    ๐Ÿˆ CTEUnknownDecades after exposureMood / behaviour changeNo โ€” but preventableEliminate head impacts
    โš ๏ธ

    Click any row above โ€” or use the sidebar โ€” to read the full clinical picture for each dementia type including symptoms, prevention evidence, and treatments.

    Global cases
    55M+
    People living with Alzheimer's worldwide
    Silent phase
    15โ€“20 yrs
    Pathology begins before any symptom
    First disease modifier
    2023
    Lecanemab โ€” 27% slowing of decline
    Preventable cases
    40%
    Through lifestyle modification (Lancet 2024)
    What is it?

    Caused by two abnormal protein deposits: amyloid-beta plaques forming between neurons and tau tangles forming inside neurons. Together they disrupt synaptic communication, trigger neuroinflammation, and cause neuronal death โ€” beginning in the hippocampus and entorhinal cortex 15โ€“20 years before any symptom appears.

    ๐Ÿ”ฌ

    Key biomarkers: Amyloid-ฮฒ42 (CSF/PET) ยท p-Tau217 blood test (90%+ accuracy) ยท APOE ฮต4 gene (increases risk 3โ€“12ร—)

    Key Symptoms
    • ๐Ÿ” Repetitive questioning โ€” each answer is forgotten immediately
    • ๐Ÿ“… Disorientation to time, date, year, or even decade
    • ๐Ÿ’ฌ Word-finding difficulty (anomia) โ€” pausing, using wrong words
    • ๐Ÿ—บ๏ธ Getting lost in familiar places โ€” spatial map dissolves
    • ๐Ÿ’ฐ Financial management failure โ€” bills, susceptibility to scams
    • ๐Ÿชž Anosognosia โ€” up to 80% unaware of their own deficits
    • ๐ŸŒ™ Sundowning โ€” increased confusion in late afternoon and evening
    Prevention โ€” Evidence Levels
    Physical Exercise
    Strong Evidence
    150 min/week moderate aerobic exercise reduces risk 30โ€“45%. Increases BDNF, promotes neurogenesis, improves cerebral blood flow. Most powerful single lifestyle intervention.
    Treat Hearing Loss Early
    Strong Evidence
    #1 modifiable risk factor (Lancet 2024). ACHIEVE trial: hearing aids reduced cognitive decline by 48% over 3 years in high-risk adults. Fit at first detection of loss โ€” do not wait.
    Blood Pressure Control
    Strong Evidence
    Every 10mmHg reduction in midlife systolic BP reduces dementia risk ~13%. SPRINT-MIND trial confirmed. Most critical in the 40โ€“65 age window โ€” midlife is when it matters most.
    Mediterranean / MIND Diet
    Good Evidence
    MIND diet reduced Alzheimer's risk by 53% in strict adherents. Leafy greens, berries, olive oil, fish, whole grains. Limit red meat, butter, and cheese.
    GLP-1 Agonists (Semaglutide)
    Phase III Trials
    Ozempic/Wegovy Phase III prevention trials ongoing. Neuroprotective and anti-inflammatory effects beyond glucose control. Results expected 2025โ€“2027.
    Cognitive Stimulation
    Good Evidence
    Higher cognitive reserve โ€” education, bilingualism, mentally demanding work โ€” delays symptom onset by years by building redundant neural circuits that compensate for early damage.
    Treatments โ€” Current and Pipeline
    DrugClassStageEffectNotes
    Donepezil (Aricept)AChE inhibitorMildโ€“SevereSymptomatic โ€” 6โ€“24 months benefitMost prescribed Alzheimer's drug worldwide since 1996
    Rivastigmine (Exelon)AChE + BuChE inhibitorMildโ€“ModeratePatch formulation reduces GI side effectsAlso approved for Parkinson's Disease Dementia
    Memantine (Ebixa)NMDA antagonistModerateโ€“SevereReduces glutamate excitotoxicityOften combined with donepezil in moderateโ€“severe stages
    Lecanemab (Leqembi)Anti-amyloid mAbEarly / MCI only27% slowing of clinical decline (18 months)FDA approved July 2023. IV infusion every 2 weeks. ARIA risk.
    Donanemab (Kisunla)Anti-amyloid mAbEarly / MCI only35% slowing in tau-low patientsFDA approved 2024. May discontinue once amyloid is cleared.
    ๐Ÿ’ก

    Key insight: Alzheimer's begins 15โ€“20 years before any symptom appears. By diagnosis, the brain has been fighting this disease silently for nearly two decades. Blood-based p-tau217 screening at GP level could soon enable detection in the silent phase โ€” when disease-modifying treatment is most powerful.

    Prevalence
    2nd
    Most common dementia type worldwide
    Decline pattern
    Stepwise
    Sudden drops after vascular events
    BP treatment effect
    20%
    Risk reduction from treating hypertension
    Mixed pathology
    50%
    Of all dementia cases at autopsy
    What is it?

    Caused by brain damage from strokes, TIAs, or small vessel disease โ€” white matter lesions and lacunar infarcts. Unlike Alzheimer's, decline is often stepwise: stable periods punctuated by sudden drops after vascular events. Executive dysfunction and gait problems frequently precede memory loss โ€” the key distinguishing feature from Alzheimer's. What protects the heart protects the brain.

    Key Symptoms
    • โšก Sudden cognitive decline after stroke โ€” stepwise, not gradual like AD
    • ๐ŸŽฏ Executive dysfunction first โ€” planning fails before memory loss
    • ๐Ÿšถ Gait disturbance โ€” often the first sign of small vessel disease
    • ๐Ÿ˜ Apathy and depression โ€” more severe and prominent than in AD
    • ๐Ÿ”€ Fluctuating cognition โ€” good days and bad days
    • ๐Ÿ˜ค Emotional lability โ€” crying or laughing disproportionately (pseudobulbar affect)
    Prevention and Treatment โ€” Proven Interventions
    Blood Pressure Control
    Proven Prevention
    Treating hypertension reduces stroke risk 35โ€“44% and vascular dementia risk 20%+. Target below 130/80 mmHg. ACE inhibitors (perindopril) may have additional neuroprotective effects beyond BP lowering.
    Treat Atrial Fibrillation
    Proven Prevention
    AF causes 20โ€“25% of all strokes through cardiac embolism. DOACs (apixaban, rivaroxaban) reduce stroke risk by 65%. AF must be actively screened for and treated in all patients over 65.
    Statin Therapy
    Strong Evidence
    High-intensity statins reduce stroke risk 25โ€“30%. Atorvastatin 80mg first-line after atherosclerotic stroke. May also directly reduce amyloid production โ€” dual benefit.
    Antiplatelet Agents
    Secondary Prevention
    Aspirin + dipyridamole or clopidogrel reduces recurrent stroke risk by 20โ€“25% after TIA or minor stroke. Dual antiplatelet for 3 weeks post-TIA then single agent long-term.
    Smoking Cessation
    Strong Evidence
    Smoking doubles stroke risk. Cessation reduces risk by 50% within 5 years. Never too late โ€” even stopping at age 70+ significantly reduces cerebrovascular risk.
    Donepezil / Memantine
    Off-label Symptomatic
    Not specifically approved for vascular dementia but commonly used. Modest symptomatic benefit. SSRIs (sertraline) for the prominent depression and emotional lability.
    ๐Ÿ’ก

    Key insight: Vascular dementia is the most preventable dementia. Blood pressure medications, anticoagulants for AF, statins, and smoking cessation can dramatically reduce its occurrence. A person who controls blood pressure, treats AF, stops smoking, and exercises regularly may prevent the majority of their vascular dementia risk entirely.

    Prevalence
    3rd
    Most common dementia type
    Diagnostic delay
    6 yrs
    Average โ€” 80% misdiagnosed first
    Wrong diagnosis first
    80%
    Usually Alzheimer's or psychiatric illness
    Antipsychotic risk
    FATAL
    Conventional antipsychotics can kill
    ๐Ÿšจ

    CRITICAL SAFETY WARNING: Conventional antipsychotics โ€” haloperidol, risperidone, olanzapine โ€” can cause severe, sometimes fatal neuroleptic sensitivity reactions in Lewy Body Dementia. If a patient has visual hallucinations + fluctuating cognition + Parkinsonism โ€” assume LBD and never administer conventional antipsychotics. Every LBD patient should carry a MedicAlert card. This single rule saves lives.

    What is it?

    Caused by alpha-synuclein protein aggregating into Lewy body inclusions inside neurons. Forms a spectrum with Parkinson's Disease Dementia (PDD) โ€” in DLB, cognitive symptoms appear first or simultaneously with motor symptoms; in PDD, motor symptoms precede dementia by more than one year. Both share identical Lewy body pathology.

    Key Symptoms โ€” Diagnostic Triad
    • ๐Ÿ‘ป Vivid visual hallucinations โ€” detailed people, animals, objects. Present in 80% of DLB. Defining feature.
    • ๐ŸŒŠ Fluctuating cognition โ€” alert one hour, profoundly confused the next
    • ๐Ÿšถ Parkinsonism โ€” rigidity, bradykinesia, shuffling gait
    • ๐Ÿ˜ด REM Sleep Behaviour Disorder (RBD) โ€” acting out dreams. Often the FIRST sign, 10โ€“15 years before dementia diagnosis
    • โฌ‡๏ธ Severe autonomic dysfunction โ€” fainting, constipation, urinary urgency
    • โš ๏ธ Antipsychotic hypersensitivity โ€” potentially fatal
    Treatments
    DrugUseEffectNotes
    Rivastigmine (Exelon)Cognition + hallucinationsBest evidence in LBDOnly drug with Level A evidence specifically in DLB
    Quetiapine (low dose)Hallucinations onlyMost tolerated atypical antipsychoticUse with caution โ€” avoid conventional antipsychotics entirely
    Pimavanserin (Nuplazid)Psychosis / hallucinationsNo motor worseningFDA approved 2016 for Parkinson's psychosis โ€” used off-label in LBD
    LevodopaMotor / ParkinsonismLess effective than in Parkinson's diseaseStart low โ€” may worsen hallucinations in some patients
    Melatonin / ClonazepamREM Sleep Behaviour DisorderReduces RBD symptoms and injury riskMelatonin preferred in elderly โ€” lower fall risk than clonazepam
    Onset age
    45โ€“65
    Most common dementia under 65
    Genetic
    60%
    Have a known genetic mutation
    Diagnostic delay
    3โ€“4 yrs
    Misdiagnosed as depression or OCD
    Progression
    Fast
    3โ€“10 years โ€” among the fastest
    What is it?

    Neurodegeneration of frontal and temporal lobes โ€” the regions controlling personality, behaviour, judgment, and speech. NOT primarily a memory disease in early stages โ€” this leads to frequent misdiagnosis as depression, bipolar disorder, or OCD. Three variants: behavioural (bvFTD โ€” personality/behaviour), Progressive Nonfluent Aphasia (PNFA โ€” speech production), and Semantic Dementia (SD โ€” loss of word meanings).

    ๐Ÿงฌ

    60% of FTD cases have a known genetic mutation: C9orf72 (most common), MAPT (tau protein), or GRN (progranulin). First-degree relatives should consider genetic counselling and testing.

    Key Symptoms
    • ๐Ÿ˜ˆ Disinhibition โ€” inappropriate remarks, shoplifting without remorse, loss of social filters
    • ๐Ÿ˜ถ Profound apathy โ€” complete loss of motivation; no distress about inaction
    • ๐Ÿ”„ Compulsive repetitive behaviours โ€” rigid routines, hoarding, tapping; mistaken for OCD
    • ๐Ÿ” Dietary changes โ€” sudden craving for sweets, gorging on food
    • ๐Ÿ’ Loss of empathy โ€” cannot feel others' pain; appears callous or psychopathic to family
    • ๐Ÿ—ฃ๏ธ Language collapse โ€” PNFA: effortful speech; SD: loss of word meanings ("what is a penguin?")
    • โœ… Memory relatively preserved early โ€” the main reason for missed diagnosis
    Treatments
    Drug / InterventionUseEffectNotes
    SSRIs (sertraline, fluvoxamine)bvFTD โ€” behavioural symptomsReduce disinhibition, compulsions, and aggressionFirst-line for bvFTD behavioural management
    TrazodoneSleep + agitationImproves sleep and reduces agitationBetter evidence in FTD than in Alzheimer's disease
    Speech & Language TherapyLanguage variants (PNFA, SD)Augmentative communication โ€” prolongs functionHigh-tech AAC devices can maintain communication for years longer
    ASOs โ€” Antisense OligonucleotidesGRN-related FTDTargeting progranulin deficiency โ€” Phase II trialFirst disease-specific therapy approaching clinical use for FTD
    ๐Ÿ’ก

    Key insight: FTD steals the personality before it steals the memory. Families watch their loved one become socially inappropriate, emotionally hollow, and impulsive โ€” while still able to tell you what they had for breakfast. Correct diagnosis prevents years of harmful psychiatric medications and connects patients to appropriate trials while still eligible.

    Reversible?
    YES
    One of the only reversible dementias
    Classic triad
    Gait ยท Urine ยท Cognition
    In that order โ€” investigate if all three present
    Shunt surgery success
    80%
    Improve significantly after VP shunt
    Most often missed as
    "Just aging"
    Tragically and preventably under-diagnosed
    What is it?

    Caused by excess cerebrospinal fluid (CSF) accumulating in brain ventricles โ€” compressing surrounding white matter. The classic triad appears in order: (1) gait disturbance first โ€” the "magnetic gait" where feet appear stuck to the floor; (2) urinary incontinence second; (3) cognitive decline third. VP shunt surgery can dramatically reverse or halt decline โ€” often within days of the procedure.

    ๐Ÿ”ฌ

    Diagnosis: Large-volume lumbar puncture โ€” remove 30โ€“50ml CSF. If walking improves within hours, NPH is confirmed and VP shunt surgery is indicated. Both diagnostic and immediately therapeutic.

    The Magnetic Gait โ€” The Most Important Sign

    The gait in NPH is clinically distinctive: wide-based, shuffling, slow โ€” feet appear literally "stuck" or "magnetic" to the floor. It resembles Parkinson's disease but appears before cognitive symptoms in 70% of NPH cases. The shuffling gait is the most important clinical clue and the first symptom to look for.

    ๐Ÿšจ

    Never attribute the triad of gait disturbance + urinary incontinence + cognitive change to "just aging." This combination in any older person warrants neurological evaluation and brain MRI to check ventricular size. Every missed NPH case is a preventable tragedy โ€” the treatment works.

    Treatments
    InterventionPurposeEffectNotes
    Large-volume lumbar punctureDiagnosis + temporary reliefGait improvement within hours confirms NPHRemoves 30โ€“50ml CSF โ€” "tap test" predicts shunt response
    VP shunt (programmable valve)Definitive surgical treatment70โ€“80% show significant improvement in gait and bladderProgrammable valve allows non-invasive pressure adjustment post-surgery
    PhysiotherapyPost-surgery rehabilitationMaximises gait improvement after shuntEarly post-operative rehabilitation is critical for best functional outcomes
    ๐Ÿ’ก

    Key insight: NPH is one of medicine's great tragedies when missed and great triumphs when caught. A person shuffling, falling, losing bladder control, and slowly losing their mind โ€” told "that is just aging" โ€” can walk out of hospital with a spring in their step days after VP shunt surgery. Every unexplained gait disturbance in an older person deserves a brain MRI.

    NFL players studied
    87%
    Of donated brains had CTE at autopsy
    Latency to symptoms
    ~20 yrs
    After the head impact exposure ends
    Approved treatments
    0
    Prevention is the only effective strategy
    Preventable?
    100%
    No head impacts = no CTE
    ๐Ÿšจ

    CTE is the first dementia we know with certainty how to prevent: stop hitting people in the head repeatedly. It is caused by human choices in sport design, rules, and culture โ€” not by genetics or aging. The consequences appear 20โ€“30 years after exposure, making cause and effect invisible to individuals making these decisions in youth. League and federation rule changes are the most powerful medical intervention available.

    What is it?

    Caused by repeated head impacts โ€” not necessarily concussions, but the thousands of subconcussive hits that never cause immediate symptoms but cumulatively destroy the brain. The tau pathology resembles Alzheimer's but distributes differently: perivascularly in the depths of sulci (cortical folds) rather than spreading from the hippocampus outward. Currently can only be definitively confirmed at autopsy.

    Symptoms โ€” In Order of Appearance
    • ๐Ÿ˜  Mood first (30sโ€“40s) โ€” depression, irritability, explosive anger; misdiagnosed as PTSD
    • ๐Ÿง  Cognition second โ€” memory problems, executive dysfunction, slowed processing
    • ๐Ÿ’” Suicidality โ€” dramatically elevated risk; Junior Seau, Dave Duerson
    • ๐Ÿ’Š Substance abuse โ€” self-medication of pain and depression
    • โšก Impulsivity and violence โ€” often directed at family members
    • ๐Ÿ” 10โ€“30 year latency โ€” cause and effect invisible to individuals in youth
    Prevention โ€” The Only Effective Strategy
    Eliminate Subconcussive Impacts
    Only Proven Strategy
    No head impacts = no CTE. Rule changes โ€” heading bans in youth football, fair catch rules in American football, head-to-head contact penalties โ€” directly reduce cumulative impact load. Helmets do NOT prevent subconcussive rotational forces.
    Age-Based Contact Sport Restrictions
    Critical
    Children under 14 should not play full-contact American football or rugby. The developing brain is dramatically more vulnerable to repeated impacts. Many medical organisations advocate removing tackling from school rugby entirely.
    Proper Concussion Protocols
    Secondary Prevention
    Rest until fully symptom-free before return to play. Never play through a concussion. Returning before full recovery dramatically increases vulnerability to the next impact โ€” and cumulative damage is the mechanism.
    Suicide Risk Management
    Clinical Priority
    All CTE patients screened for suicidality at every clinical contact. CTE carries very high and well-documented suicide risk. Crisis intervention is life-saving in this population.
    Long-term risk
    80%
    Of Parkinson's patients develop dementia
    Onset after PD diagnosis
    6โ€“10 yrs
    Average time before dementia appears
    First approved drug
    2006
    Rivastigmine โ€” Level A evidence in PDD
    Key distinction from DLB
    Motor first
    Motor symptoms must precede cognition by 1+ year
    What is it?

    When established Parkinson's Disease develops significant dementia โ€” cognitive symptoms appearing more than 1 year after motor symptom onset. Both PDD and DLB share identical alpha-synuclein Lewy body pathology. Characterised by executive dysfunction, attention failure, visuospatial problems, and hallucinations โ€” rather than the profound amnesia of Alzheimer's.

    Key Symptoms
    • ๐Ÿงฉ Executive function failure โ€” planning, organising, multitasking
    • ๐Ÿ‘ป Visual hallucinations โ€” detailed people and animals
    • ๐Ÿ˜ด REM Sleep Behaviour Disorder โ€” acting out dreams
    • โฌ‡๏ธ Orthostatic hypotension โ€” dizziness on standing, falls
    • ๐Ÿ˜” Depression and anxiety โ€” present in 40โ€“60%
    • ๐Ÿ” Attention breakdown before memory loss
    Treatments
    DrugUseNotes
    Rivastigmine (Exelon)CognitionFDA approved specifically for PDD 2006. 27% reduction in decline. Patch preferred.
    Pimavanserin (Nuplazid)HallucinationsNo motor worsening. FDA approved 2016 for Parkinson's psychosis.
    Levodopa/CarbidopaMotor symptomsGold standard for Parkinson's motor control. Does not treat cognition.
    SSRIs (sertraline)DepressionAvoid amitriptyline โ€” anticholinergic effects worsen cognition.
    ๐Ÿ’ก

    Key insight: Vigorous aerobic exercise has the best evidence of any intervention for neuroprotection in Parkinson's. High-intensity treadmill training, cycling, boxing (non-contact) โ€” 3โ€“5 sessions per week. Exercise increases BDNF and may directly slow alpha-synuclein aggregation.

    Ireland estimate
    ~5,700
    People in Ireland with young-onset dementia
    Diagnostic delay
    5 years
    Average โ€” age bias causes missed diagnosis
    Most common cause
    FTD under 60
    Frontotemporal dementia most common under 60
    Reversible causes
    Many
    Always exclude treatable causes first
    Causes to Exclude First
    Many causes of young-onset dementia are treatable or reversible
    Vitamin B12 Deficiency
    Can cause severe cognitive impairment that is fully reversible with B12 injections if caught early. Always check serum B12 in anyone under 65 with cognitive decline.
    Autoimmune Encephalitis
    Anti-NMDA receptor encephalitis and others โ€” treatable with steroids, IVIG, or plasma exchange. 80% recover significantly with early treatment. Check anti-NMDA, anti-LGI1, anti-CASPR2 antibodies.
    Thyroid Disease
    Hypothyroidism causes cognitive slowing that reverses completely with thyroxine treatment. Check TSH in every young-onset case.
    Normal Pressure Hydrocephalus
    Can occur in younger adults. Gait disturbance + cognitive decline + urinary urgency โ€” investigate with MRI and lumbar puncture.
    Brain Tumour
    Frontal lobe tumours can mimic FTD with personality change. Always perform MRI brain before accepting a neurodegenerative diagnosis in young-onset cases.
    The Human Impact
    ๐Ÿ’”

    Young-onset dementia arrives when children still need parenting, mortgages are unpaid, and identity is bound to career. Standard older-adult services are almost entirely inappropriate for this group.

    ๐Ÿ’ผ

    Employment: The person may still be working when symptoms begin. Colleagues notice errors before family does. Occupational health referral and reasonable adjustments can extend working life.

    ๐Ÿ’ฐ

    Financial: Mortgage protection insurance may cover dementia. Income protection policies may activate. Disability Allowance is available under 66. Contact Citizens Information: 0818 07 4000.

    ๐Ÿ‘จโ€๐Ÿ‘ฉโ€๐Ÿ‘ง

    Children: Age-appropriate honest communication with children is vital. Young Carers Ireland (youngcarers.ie) provides specific support for children who are caring for a parent with dementia.

    At autopsy
    50%
    Of dementia cases have mixed pathology
    Most common mix
    AD + Vascular
    Alzheimer's plus vascular disease
    Clinical diagnosis
    Often missed
    Single diagnosis usually given in life
    Implication
    Treat all factors
    Target every contributing pathology
    What is it?

    Mixed dementia occurs when a person has more than one type of dementia pathology simultaneously. The most common combination is Alzheimer's disease pathology (amyloid plaques and tau tangles) alongside vascular damage (white matter lesions, lacunar infarcts). This is found at autopsy in approximately 50% of all dementia cases โ€” meaning the single diagnosis most people receive during life understates the true complexity of what is happening in the brain.

    ๐Ÿ”ฌ

    Lewy body pathology is also commonly found alongside Alzheimer's pathology โ€” making the triad of AD + vascular + Lewy bodies a frequent autopsy finding in elderly dementia patients.

    Why It Matters
    Faster progression
    Having two pathologies typically means faster cognitive decline than either condition alone. The two types of damage are synergistic โ€” each makes the other worse.
    Atypical symptoms
    Mixed dementia often presents with features of both conditions โ€” stepwise decline (vascular) combined with progressive memory loss (Alzheimer's) โ€” making clinical diagnosis harder.
    Treatment implications
    Treating only one pathology is not enough. Blood pressure control, cholesterol management, and antiplatelet therapy are needed alongside donepezil and memantine.
    Prevention is doubly important
    Cardiovascular risk management โ€” BP, cholesterol, AF treatment, smoking cessation โ€” benefits both the vascular AND the Alzheimer's component by protecting the blood-brain barrier.
    Cause
    Thiamine (B1) deficiency
    Usually from chronic heavy alcohol use
    Reversible?
    25% fully
    If treated early with IV thiamine
    Ireland alcohol deaths
    1,500+
    Per year โ€” alcohol a major dementia risk
    Prevention
    100%
    Preventable โ€” stop alcohol, take thiamine
    What is it?

    Korsakoff syndrome is caused by severe thiamine (Vitamin B1) deficiency โ€” most commonly from chronic heavy alcohol use, which both reduces thiamine intake and impairs thiamine absorption. It damages the mammillary bodies and thalamus โ€” structures critical for memory formation. The defining feature is confabulation: the person unconsciously invents detailed, plausible memories to fill the gaps โ€” they are not lying, they genuinely believe their fabricated accounts.

    Key Symptoms
    • ๐Ÿ•ณ๏ธ Severe anterograde amnesia โ€” cannot form any new memories
    • ๐Ÿ“– Confabulation โ€” invents detailed false memories without knowing it
    • ๐Ÿ‘€ Eye movement abnormalities โ€” nystagmus, gaze palsy
    • ๐Ÿšถ Ataxia โ€” unsteady gait, coordination problems
    • ๐Ÿ˜ถ Apathy and flat affect โ€” little emotional response
    • ๐Ÿ”™ Retrograde amnesia โ€” gaps in memories from years before onset
    ๐Ÿšจ

    Wernicke's Encephalopathy is a medical emergency that precedes Korsakoff syndrome. Classic triad: confusion + eye movement abnormalities + ataxia. If suspected, give IV thiamine (Pabrinex) immediately before any glucose โ€” giving glucose first without thiamine can precipitate irreversible brain damage. Every A&E should follow this protocol for alcohol-dependent patients.

    ๐Ÿ“ž

    Alcohol Action Ireland: 01 878 0610 ยท Drinkaware Ireland: drinkaware.ie ยท AA Ireland: aa.ie ยท HSE Drug & Alcohol Helpline: 1800 459 459

    Ireland cases per year
    ~3โ€“5
    Approximately 1โ€“2 per million population
    Progression
    Weeksโ€“months
    Fastest of all dementias โ€” weeks to death
    Cause
    Prion protein
    Misfolded PrP protein โ€” no virus, no bacteria
    Variant CJD (vCJD)
    Linked to BSE
    "Mad cow disease" โ€” UK epidemic 1990s
    Types of CJD
    Sporadic CJD (sCJD)
    85% of cases
    No known cause. Appears spontaneously. Average onset age 65. Rapid progression โ€” median survival 4โ€“6 months from diagnosis. Characteristic EEG and MRI findings. 14-3-3 protein in CSF.
    Familial CJD (fCJD)
    10โ€“15% of cases
    Caused by inherited mutations in the PRNP gene. Earlier onset than sporadic. Genetic counselling for family members essential. Fatal Familial Insomnia is a related prion disease.
    Variant CJD (vCJD)
    Rare โ€” linked to BSE
    Acquired from eating BSE-contaminated beef. UK epidemic 1990sโ€“2000s. Younger onset (average 29 years). Longer course (13 months). Psychiatric symptoms predominate early.
    Iatrogenic CJD (iCJD)
    Very rare
    Transmitted through contaminated surgical instruments, corneal grafts, or cadaveric growth hormone (pre-1985). Stringent sterilisation protocols have made this extremely rare.
    Key Symptoms โ€” Rapid Onset
    • โšก Rapidly progressive dementia โ€” weeks not years
    • ๐Ÿคธ Myoclonus โ€” sudden involuntary muscle jerks, often startle-triggered
    • ๐Ÿ‘๏ธ Visual disturbances and hallucinations
    • ๐Ÿšถ Cerebellar ataxia โ€” severe coordination failure
    • ๐Ÿ˜ด Akinetic mutism in late stages โ€” awake but unresponsive
    • ๐Ÿง  Characteristic MRI findings โ€” cortical ribboning, basal ganglia signal
    ๐Ÿšจ

    CJD is a notifiable disease in Ireland. All suspected cases must be reported to the HPSC. There is no treatment โ€” care is palliative. The National CJD Research & Surveillance Unit (UK) maintains the international registry.

    Of Alzheimer's cases
    ~5%
    But widely underdiagnosed
    Typical onset age
    50โ€“65
    Younger than typical Alzheimer's
    Diagnostic delay
    3โ€“4 yrs
    Seen by optometrists first โ€” eyes are fine
    Pathology
    Alzheimer's
    100% have AD pathology at autopsy
    What is it?

    PCA is a syndrome โ€” most commonly caused by Alzheimer's pathology โ€” in which neurodegeneration targets the posterior brain regions (parietal, occipital, posterior temporal cortices) rather than the hippocampus first. The result is devastating: the person loses the ability to read, write, drive, navigate space, recognise objects by sight, and calculate โ€” while their episodic memory and verbal fluency may remain largely intact for years. It is profoundly under-diagnosed because clinicians do not expect Alzheimer's in a 57-year-old who still knows what year it is.

    Key Symptoms
    • ๐Ÿ“– Cannot read โ€” letters visible but uninterpretable (alexia)
    • โœ๏ธ Cannot write legibly โ€” visuomotor coordination fails (agraphia)
    • ๐Ÿš— Driving becomes impossible โ€” cannot judge distances or read signs
    • ๐Ÿช’ Cannot use familiar tools โ€” dressing apraxia
    • ๐Ÿ”ข Arithmetic fails โ€” cannot read a clock face (acalculia)
    • ๐Ÿ–ผ๏ธ Object agnosia โ€” cannot recognise objects by sight, only by touch
    • โœ… Memory relatively preserved early โ€” the main diagnostic confusion
    • ๐Ÿ˜ฐ Severe anxiety โ€” living in a world that no longer makes visual sense
    ๐Ÿ’ก

    Key insight: PCA is Alzheimer's wearing a disguise. The patient seems too young, too articulate, and too sharp โ€” because they are. Any person under 65 with progressive visuospatial decline and normal episodic memory should be referred urgently to a cognitive neurologist. The diagnostic odyssey currently averages 3โ€“4 years โ€” this must be shortened.

    Develop Alzheimer's pathology
    ~100%
    By age 40 โ€” plaques form from adolescence
    Develop clinical dementia
    75%
    By age 65
    Ireland โ€” people with DS
    ~7,000
    Estimated โ€” Down Syndrome Ireland
    Why it happens
    Chromosome 21
    Carries the APP (amyloid) gene โ€” 3 copies
    Why the Connection is Absolute

    Every person with Down syndrome has three copies of chromosome 21, which carries the APP (amyloid precursor protein) gene. This causes lifelong overproduction of amyloid-beta protein โ€” on average 1.5ร— normal levels from birth. Amyloid plaques begin forming in the brain during adolescence โ€” 30+ years before any dementia symptoms. By age 40, virtually all individuals with Down syndrome have full Alzheimer's pathology on PET scan. Most develop clinical dementia between ages 50โ€“65. Down syndrome is therefore the most penetrant genetic model of Alzheimer's disease in the world.

    Monitoring & Support
    Annual cognitive monitoring from age 30
    Establish a cognitive baseline before any decline begins. Down Syndrome Ireland recommends annual health checks from age 30 including memory and cognitive assessment.
    Recognise early signs
    Early signs in Down syndrome often differ from typical Alzheimer's: personality change, loss of skills, seizures (new onset in adulthood), and changes in daily living abilities may appear before memory loss.
    Clinical trials
    People with Down syndrome are now a primary target population for Alzheimer's prevention trials โ€” including anti-amyloid antibody studies. Participation can be life-changing for the whole community.
    Ireland support
    Down Syndrome Ireland: downsyndromeirl.com ยท 01 426 6500. Provides specialist dementia support, carer training, and connects families with appropriate services as cognitive decline progresses.